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Summary
In the past few years, many patients have been described
who have a defect of unknown origin in the peroxisomal
b-oxidation pathway. Complementation analysis has
been done by various groups to establish the extent of
the genetic heterogeneity among the patients. These
studies were based on the use of two established cell
lines, one with a deficiency of acyl-CoA oxidase and one
with a deficiency of L–bifunctional protein (L-BP), and
they showed that most patients belong to the L-
BP–deficient group. However, molecular analysis of the
cDNA encoding L-BP in patients failed to show any mu-
tations. The recent identification of a new D-specific bi-
functional protein (D-BP) prompted us to reinvestigate
the original patient with presumed L-BP deficiency. In a
collaborative effort, we have now found that the true
defect in this patient is at the level of the D-BP and not
at the level of the L-BP. Our results suggest that most,
if not all, patients whose condition has been diagnosed
as L-BP are, in fact, D-BP deficient. We tested this hy-
pothesis in nine patients whose condition was diagnosed
as L-BP deficiency on the basis of complementation anal-
ysis and found clear-cut mutations in the D-BP cDNA
from all patients.
Introduction
b-Oxidation of fatty acids is a vital function of eukar-
yotic cells. Fatty acid oxidation can proceed both in
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mitochondria and in peroxisomes via a four-step path-
way involving dehydrogenation, hydratation, dehydro-
genation again, and thiolytic cleavage. There are major
differences between the mitochondrial and peroxisomal
b-oxidation systems in regard to both their enzymatic
organization and their precise role in cellular fatty acid
oxidation. Mitochondria are involved in the b-oxidation
of the bulk of fatty acids derived from our daily diet,
whereas peroxisomes play an indispensable role in the
oxidation of very-long–chain fatty acids, branched-chain
fatty acids such as pristanic acid, and bile acid inter-
mediates such as dihydroxycholestanoic and trihydroxy-
cholestanoic acid (THCA).
It has been shown that multiple enzymes are involved
in each step of the peroxisomal b-oxidation pathway. In
humans two acyl-CoA oxidases with different substrate
specificities have been identified, one for straight-chain
fatty acids and one for 2-methyl branched-chain fatty
acids (Vanhove et al. 1993). Furthermore, two different
thiolases are involved in the last step of the b-oxidation
spiral: Straight-chain fatty acids are thiolytically cleaved
by the conventional thiolase (Miyazawa et al. 1981; An-
tonenkov et al. 1997), whereas 2-methyl branched-chain
fatty acids are thiolytically cleaved by sterol-carrier pro-
tein 2/3-oxoacyl-CoA thiolase (Antonenkov et al. 1997;
Wanders et al. 1997; Bunya et al. 1998), which contains
both thiolase activity and sterol-carrier protein activity.
In addition, a new bifunctional protein with a substrate
specificity quite different from that of the original bi-
functional protein was recently described. Unlike the
other bifunctional protein, which produces an L-3-hy-
droxyacyl-CoA as intermediate, this newly identified en-
zyme generates a D-hydroxyacyl-CoA intermediate
(Dieuaide-Noubhani et al. 1996; Jiang et al. 1996; Jiang
et al. 1997a, 1997b; Qin et al. 1997b). On the basis of
these findings, the two proteins have been named
“L–bifunctional protein” (L-BP) and “D–bifunctional
protein” (D-BP) (Jiang et al. 1997a, 1997b). Both bi-
functional proteins accept straight-chain enoyl-CoAs as
substrates, but they differ with respect to other enoyl-
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CoAs such as the enoyl-CoA ester of THCA, which is
accepted only by the D-specific enzyme (Jiang et al.
1997a; Qin et al. 1997a, 1997b).
In patients with L-BP deficiency one would expect el-
evated very-long–chain fatty acids with normal bile acid
intermediates. Watkins and coworkers (1989), on the
basis of immunoblot analysis performed in postmortem
liver material and fibroblasts, concluded that the patient
they analyzed lacked L–bifunctional enzyme. Neverthe-
less there was accumulation of both very-long–chain
fatty acids and bile acid intermediates, which is hard to
reconcile with an isolated deficiency of L-BP. Since fi-
broblasts from the patient of Watkins and coworkers
(1989) are generally used as the reference cell line for
complementation analysis (Wanders et al. 1992; Mc-
Guinness et al. 1993; Suzuki et al. 1994; Moser et al.
1995; Watkins et al. 1995; Paton et al. 1996; Wanders
et al. 1996; van Grunsven et al. 1997; van Grunsven
and Wanders 1997), it is important to establish the true
genetic basis of bifunctional enzyme deficiency in this
patient.
The results described in this paper provide evidence
suggesting that the true genetic defect in the patient an-
alyzed by Watkins et al. (1989) is in the gene coding for
D-BP and not in the gene coding for L-BP. We have used
this newly acquired knowledge to identify the molecular
basis of the genetic defect in nine patients classified as
L-BP deficient by means of complementation analysis
(van Grunsven and Wanders 1997).
Patients and Methods
Patient T.C.
Patient T.C.’s clinical and biochemical characteristics
have been described elsewhere (Watkins et al. 1989).
Fatty Acid Oxidation in Cultured Skin Fibroblasts
Pristanic acid b-oxidation in patient T.C. was mea-
sured as described by Wanders et al. (1995).
Cell Culture Conditions and Preparation of Extracts
Fibroblasts were cultured in HAM-F10 medium
(Gibco BRL) supplemented with 10% FCS (Bio-Whit-
taker). The cells were trypsinized, washed with PBS, and
spun down. Cell pellets were stored at 80C until they
were used. The cell pellets were resuspended in PBS,
0.25% Triton X-100, 1 mg/ml Pefabloc (Merck), and 10
mg/ml leupeptine (Boehringer Mannheim) and sonicated
twice. Liver samples were homogenized in the same buf-
fer and sonicated three times. The homogenates were
centrifuged at 10,000 g for 5 min and the supernatants
were preserved.
Immunoblot Analysis
SDS-PAGE was conducted as described by Laemmli
(1970). For immunoblot analysis, proteins were trans-
ferred from 10% (w/v) acrylamide gels to nitrocellulose
paper. After undergoing blocking with 5% Protifar (Nu-
tricia) in PBS/0.1% Tween-20 for 1 h, the blots were
incubated for 2 h with rabbit polyclonal antibodies
raised against D-BP or L-BP diluted in 3 mg/ml BSA. The
antibodies raised against human D-BP (preparation II)
and L-BP have been characterized elsewhere (Jiang et al.
1996; Suzuki et al. 1997). After being washed five times
with PBS/0.1% Tween-20, the blots were incubated for
1 h with goat anti–rabbit IgG (HL) alkaline phospha-
tase (Biorad) in 5% Protifar in PBS/0.1% Tween-20. The
blots were then washed five times with PBS/0.1% Tween-
20 and stained with 0.33 mg/ml nitro blue tetrazolium
(Biorad) and 0.165 mg/ml 5-bromo-4-chloro-3-indolyl
phosphate (Biorad) in 100 mM Tris-HCl buffer, at 9.5
pH, containing 100 mM NaCl and 5 mM MgCl2.
Immunofluorescence Analysis
Cultured fibroblasts were washed twice with 10 mg/
ml BSA in PBS and fixed for 20 min with 2% parafor-
maldehyde in PBS/0.1% Triton X-100. Cells were
washed twice with PBS/0.1% Triton X-100, and free
aldehyde groups were blocked by incubating for 10 min
in 0.1 M NH4Cl in PBS. Cells were washed three times
with 10 mg/ml BSA in PBS and incubated for 45 min
with anti–D-BP (see Immunoblot Analysis) or anticata-
lase (Heikoop et al. 1991). Cells were washed three times
with 10 mg/ml BSA in PBS, incubated for 30 min with
biotinylated donkey anti–rabbit Ig (Amersham), and
stained with streptavidin-labeled fluorescein isothio-
cyanate (streptavidin-FITC) (Gibco BRL).
Measurement of D-BP
The combined activity of the enoyl-CoA hydratase
and 3-hydroxyacyl-CoA dehydrogenase components of
the D-BP was measured as described elsewhere (van
Grunsven et al. 1998). Fibroblast homogenates were in-
cubated for 60 min at 37C in a medium containing 50
mM Tris-HCl at 8.5 pH, 1 mM NAD, 150 mM KCl,
0.1 mM (24E)-3a,7a,12a-trihydroxy-5b-cholest-24-en-
oyl-CoA (24-ene-THC-CoA; prepared as described by
Xu and Cuebas [1996]), 5 mM pyruvate, and 18 U/ml
lactate dehydrogenase. The final protein concentration
was 150 mg/ml. Reactions were terminated by addition
of 2 M HCl to a final concentration of 0.18 M followed
by neutralization to a pH of ∼5.0 by addition of 0.6 M
MES plus 2 M KOH. Resolution of the different CoA-
esters was achieved essentially as described by Xu and
Cuebas (1996).
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Table 1
Activity Measurements of Pristanic Acid b-Oxidation and D-BP in
Fibroblasts
Parameter Measured
Patient
T.C. Controls
Peroxisomal b-oxidation
(nmol/h/mg protein):
Pristanic acid as substrate 13a (74)b1,030 475
47a
97a
4a
D-BP activity (nmol/min/mg
protein):
Enoyl-CoA hydratasec .05 (10)b.28 .02
D-hydroxyacyl-CoA dehy-
drogenased NDe (10)b.11 .02
a Four separate experiments were conducted.
b Values listed represent mean  SD ( ).n 1
c Production of 24-hydroxy-THC-CoA.
d Production of 24-keto-THC-CoA.
e ND  not detectable.
RNA Isolation and cDNA Synthesis
We isolated total RNA from cultured skin fibroblasts
(stored at 80C) by following the acid guanidium thi-
ocyanate-phenol-chloroform extraction procedure de-
scribed by Chomczynski and Sacchi (1987) and subse-
quently used to prepare cDNA (Ijlst et al. 1994).
PCR and Sequencing
The cDNAs encoding either L-BP or D-BP were am-
plified in three overlapping fragments by means of prim-
ers with 21M13 or universal M13 extensions (5′-tgt
aaa acg acg gcc agt-3′ and 5′-cag gaa aca gct atg acc-3′,
respectively).
L-BP.—(1) Fragment 1 (bases 57 to 737; ATG1;
Hoefler et al. 1994; Fukuda et al. 1998) was amplified
with primers 5′-tgt aaa acg acg gcc agt GGA AAA GTG
GTT TGC CTG (sense) and 5′-cag gaa aca gct atg acc
TCA TAG GGA TAC TGC ACA GC-3′ (antisense). (2)
Fragment 2 (bases 649 to 1,581) was amplified with
primers 5′-tgt aaa acg acg gcc agt TCT TGA AGA TGC
GGA GGC AGC-3′ (sense) and 5′-cag gaa aca gct atg
acc CAA CCC AGC AAG ATC AGA CAC-3′ (antisense).
(3) Fragment 3 (bases 1,408 to 2,212) was amplified
with primers 5′-tgt aaa acg acg gcc agt GGA GTC GTT
GTA GGC AAC TG-3′ (sense) and 5′-cag gaa aca gct
atg acc ACC TGA TGC TAG CAT GTG AG-3′
(antisense).
D-BP.—(1) Fragment 1 (bases 48 to 806; ATG1;
Adamski et al. 1995) was amplified with primers 5′-tgt
aaa acg acg gcc agt GGC CAG CGC GTC TGC TTG
TTC-3′ (sense) and 5′-cag gaa aca gct atg acc ACT GCC
TCA GGA GTC ATT GG-3′ (antisense). (2) Fragment
2 (bases 675 to 1,543) was amplified with primers 5′-
tgt aaa acg acg gcc agt TTG TCA CGA GAG TTG TGA
GG-3′ (sense) and 5′-cag gaa aca gct atg acc GTA AGG
GAT TCC AGT CTC CAC-3′ (antisense). (3) Fragment
3 ( bases 1,489 to 2,313) was amplified with primers 5′-
tgt aaa acg acg gcc agt ACC TCT CTT AAT CAG GCT
GC-3′ (sense) and 5′-cag gaa aca gct atg acc CCC TGC
ATC TTA GTT CTA ATC AC-3′ (antisense).
PCR reactions (final volume, 25 ml) contained 2–5 ml
cDNA, 10 mM Tris-HCl (at 8.4 pH), 50 mM KCl, 0.1
mg/ml BSA, oligonucleotide primers as indicated (12.5
pmol each), 1.5–2.0 mM MgCl2, and 2.5 U Taq poly-
merase. Thermocycling conditions consisted of 120 s at
96C from initial to cycling and 30 cycles of 30 s at
94C, 30 s at 55C, and 90 s at 72 ˚C, followed by 10
min of extension at 72C.
We performed sequence analysis of the PCR fragments
after we purified the fragments from the PCR reaction
mixtures with the Prep-A-Gene DNA purification system
(Biorad). We sequenced sense and antisense strands with
21M13 and universal M13 (M13rev) fluorescent prim-
ers, respectively, on an Applied Biosystems 377A auto-
mated DNA sequencer in keeping with standard pro-
tocols provided by the manufacturer.
Subcloning of PCR-Amplified Fragments and
Sequencing
To separate the two cDNAs of L-BP, we amplified the
cDNA encoding L-BP with primers 5′-tgt aaa acg acg gcc
agt GGA GTC GTT GTA GGC AAC TG-3′ (sense) and
5′-cag gaa aca gct atg acc ACC TGA TGC TAG CAT
GTG AG-3′ (antisense) and ligated the cDNA into a
pGEM-T vector (pGEM-T Vector System; Promega). For
sequencing, we amplified the inserts of the plasmids with
the same primers and sequenced the PCR products as
described above.
Results
Pristanic Acid b-Oxidation
Patient T.C. was previously described as the first pa-
tient with L-BP deficiency (Watkins et al. 1989). Ab-
normal levels of very-long–chain fatty acids were found
in both plasma and fibroblasts, and elevated levels of
THCA were found in plasma. In addition, C24:0 b-ox-
idation was deficient in fibroblasts from the patient
(Watkins et al. 1989). We have now extended these stud-
ies and have found that oxidation of pristanic acid, a 2-
methyl fatty acid, is also deficient in the patient’s fibro-
blasts (table 1). These data are hard to reconcile with
an isolated deficiency of L-BP, since it is now known that
the enoyl-CoA ester of pristanic acid is primarily if not
exclusively handled by the newly recognized D-BP (Jiang
et al. 1997a).
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Figure 1 Immunofluorescence analysis of fibroblasts with anti–D-BP and anticatalase. a, Control (C1) fibroblasts, stained with anti–D-
BP. b, Fibroblasts from patient T.C., stained with anti–D-BP. c, Fibroblasts from a Zellweger patient (Z1), stained with anti–D-BP. d, Control
(C1) fibroblasts, stained with anticatalase. e, Fibroblasts from patient T.C., stained with anticatalase. f, Fibroblasts from a Zellweger patient
(Z1), stained with anticatalase.
D-BP Measurements
The recent identification of D-BP, which reacts with
the enoyl-CoA esters of straight-chain fatty acids, 2-
methyl branched-chain fatty acids, and bile acid inter-
mediates, prompted us to focus on this enzyme as the
potential primary defect in this patient. We incubated
fibroblast homogenates with the enoyl-CoA ester of
THCA, which is handled by D-BP but not by L-BP, and
measured the formation of 24-hydroxy-THC-CoA and
24-keto-THC-CoA by high-performance liquid chro-
matography. As shown in table 1, formation of both 24-
hydroxy-THC-CoA and 24-keto-THC-CoA was
strongly deficient in fibroblast homogenates from the
patient.
Analysis of D-BP by Immunoblot and
Immunofluorescence Analyses
The recent generation of a good antibody against D-
BP (see Jiang et al. 1996 for details) allowed studies at
the protein level. As shown in figure 1, a punctate flu-
orescence pattern of peroxisomes was found in control
fibroblasts (fig. 1a), whereas a faint but diffuse pattern
of immunofluorescence in the cytosol was detected in
the patient’s fibroblasts (fig. 1b). We observed that the
nuclei in the patient’s fibroblasts were highly fluorescent
and irregularly shaped. When we used antibodies against
catalase, we observed a punctate fluorescence pattern of
peroxisomes in the patient’s fibroblasts (fig. 1e). The
immunofluorescent particles were enlarged and reduced
in number in comparison to those in control fibroblasts
(fig. 1d). This observation is in accordance with obser-
vations based on fibroblasts from other patients with a
defect in peroxisomal b-oxidation (Suzuki et al. 1994).
In tissue samples from patients with Zellweger syn-
drome, whose fibroblasts lack peroxisomes because of
a defect in peroxisome biogenesis, we found a diffuse
immunofluorescence pattern in the cytosol when we
performed immunofluorescence, both with anti–D–bi-
functional enzyme and with anticatalase (fig. 1c and f).
These data show that peroxisomes were normally pre-
sent in the patient’s fibroblasts but that D–bifunctional
enzyme was strongly deficient. We were not able to per-
form immunofluorescence with the antibody against L-
BP (see also Suzuki et al. 1997).
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Immunoblot analysis confirmed the finding that D-BP
was absent in the liver and fibroblasts of the patient (fig.
2). In control livers and fibroblasts, not only the full-
length protein of 79 kD but also the two proteolytically
processed polypeptides were present: the 45-kD band,
corresponding to the enoyl-CoA hydratase component
of D-BP, and the 35-kD band, corresponding to the 3-
hydroxyacyl-CoA dehydrogenase component of D-BP
(Leenders et al. 1994a, 1994b; Dieuaide-Noubhani et
al. 1996; Jiang et al. 1996; Jiang et al. 1997b; Qin et
al. 1997b). None of these bands were present in liver
tissue or fibroblasts from the index patient. In Zellweger
patients, minor amounts of the full-length protein were
present in liver tissue, whereas about half the normal
amount of full-length protein was present in fibroblasts.
Only trace amounts of the processed components were
present in liver samples from Zellweger patients,
whereas these components could not be detected at all
in fibroblasts from the Zellweger patients.
Using newly generated antibodies raised against L-BP,
we found that L-BP was normally present in both liver
tissue and fibroblasts of the patient (fig. 2). In fibroblasts
many aspecific bands were present, but all bands were
present in fibroblasts of the index patient. However, the
suspected band for L-BP is specifically abolished by im-
munoprecipitation (see Jiang et al. 1997a), and this band
was not detectable in fibroblasts from Zellweger pa-
tients. Furthermore, trace amounts of L-BP could be de-
tected in liver tissue from Zellweger patients.
Resolution of the Molecular Basis of BP Deficiency
To identify the molecular basis of the deficiency of D-
BP, we amplified the cDNA encoding D–bifunctional en-
zyme by PCR via three overlapping primer sets and sub-
sequently sequenced the PCR products. Figure 3 shows
that the cDNA of the patient had deletions at bp 422
and bp 423 of the cDNA, which causes a frameshift
resulting in a truncated protein.
To determine whether the patient was homozygous
for this deletion, we amplified the exon in which the
deletion is located and parts of the surrounding introns,
following the intron sequences worked out by Leenders
and coworkers (in press). Sequence analysis revealed
only the deleted sequence, which suggests that the pa-
tient might indeed be homozygous for the mutation (re-
sults not shown). Unfortunately, no material from the
parents was available for analysis.
We also analyzed the cDNA encoding L-BP in the pa-
tient’s cells to be sure that L-BP was not defective in the
patient. Two cDNAs were found that most likely cor-
responded to the maternal and paternal alleles. Sequenc-
ing of these cDNAs revealed that the sequence of one
cDNA was indistinguishable from the wild-type se-
quence, whereas in the second cDNA two nucleotide
alterations were found (bp 2050 and bp 2066), leading
to ArgrGly and IlerThr amino acid substitutions at
positions 684 and 689, respectively (see Discussion). The
two (heterozygous) mutations were not present in the
cDNA encoding L-BP of 24 control individuals. How-
ever, the presence of (at least) one normal allele for L-
BP and the finding of normal L-BP levels via immunoblot
analysis in both liver tissue and fibroblasts from the pa-
tient (fig. 2) argue against L-BP deficiency as the under-
lying basis for the deficient peroxisomal b-oxidation in
this patient.
Analysis of D-BP cDNA in Additional Patients
Classified as L-BP Deficient
Many patients have been classified as L-BP deficient
on the basis of complementation studies that use cells
from patient T.C. as the reference cell line (Wanders et
al. 1992; McGuinness et al. 1993; Suzuki et al. 1994;
Moser et al. 1995; Watkins et al. 1995; Paton et al. 1996;
Wanders et al. 1996; van Grunsven et al. 1997; van
Grunsven and Wanders 1997). To ascertain whether
these patients were also affected in the gene coding for
D-BP, we performed sequence analysis of the cDNA cod-
ing for D-BP in a series of nine patients identified else-
where by two of us (van Grunsven and Wanders 1997).
The results, presented in table 2, show a series of dif-
ferent mutations in the D-BP cDNA, including two mis-
sense mutations (Gly16Ser and Leu21Phe), a 66-bp de-
letion (1438-1503del), a 342-bp deletion (281-622del),
and a 13-bp deletion (869-881del). All mutations were
found to be homozygous at the cDNA level. The parents
of patient 1, patient 2, and patient 9 are consanguineous,
suggesting that these patients are indeed homozygous
for the mutations found. Whether the other patients are
truly homozygous for the mutations identified or het-
erozygous, with the other allele being a null allele, re-
mains to be established. Studies at the genomic level are
under way to resolve this.
We also performed sequence analysis of the L-BP
cDNA, and we found no mutations in our series of nine
patients.
Discussion
The patient studied in this paper is known in the lit-
erature as the only patient with a documented deficiency
of the L-BP, as established by Watkins and coworkers
(1989). L-BP deficiency was confirmed from the fact that
immunoblot analysis detected no L-BP in postmortem
liver and fibroblast fractions, whereas its corresponding
mRNA was found to be normally present. Earlier studies
of plasma from the patient had shown elevated levels of
very-long–chain fatty acids and of THCA. Until recently
these data were generally explained on the basis of the
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Figure 2 Immunoblot analysis of D-BP and L-BP in liver tissue (5 mg protein) and fibroblasts (50 mg protein) of five controls (C1–C5),
three Zellweger patients (Z1–Z3), and patient T.C. Arrowheads indicate the D-BP and L-BP.
Figure 3 Mutation analysis of D-BP. Electropherograms show
that patient T.C. is homozygous (on cDNA) for a deletion of 2 bp.
The deleted base pairs are underlined in the electropherogram of the
control.
belief that L-BP catalyzes the hydration and dehydro-
genation of all enoyl-CoA esters, including the enoyl-
CoAs of straight-chain fatty acids, of 2-methyl
branched-chain fatty acids such as pristanic acids, and
of bile acid intermediates such as THCA. The recent
discovery that L-BP is not able to convert the enoyl-CoA
esters of THCA (Xu and Cuebas 1996; Jiang et al.
1997a) and pristanic acid (Dieuaide-Noubhani et al.
1997; Jiang et al. 1997a) to their b-keto-acyl-CoAs was
hard to reconcile with the conclusion that the index pa-
tient’s condition was truly L-BP deficiency.
Our present data show that the defect in this patient
is indeed D-BP deficiency. We conclude this on the basis
of the following findings: (1) deficient activity of D-BP
as shown enzymatically in fibroblast homogenates (table
1); (2) absence of D-BP as shown by immunofluorescence
analysis (fig. 1) and immunoblot analysis (fig. 2); and
(3) the identification of a homozygous deletion of 2 bp
on the basis of studies at the cDNA (fig. 3) and genomic
levels. The deletion of these 2 bp at position 422 and
423 of the cDNA causes a frameshift leading to a pre-
mature stop codon at position 490, which results in a
shortened product of 163 amino acids (17.5 kD). This
protein lacking 573 amino acids is probably fully in-
active since it lacks the catalytic amino acids tyrosine
and lysine in the NYSAAK-motif characteristics of the
short-chain–alcohol dehydrogenase gene family (Kro-
zowski 1992). In addition, the truncated protein also
lacks the C-terminus required for correct targeting of the
protein to the peroxisomes. Indeed, D-BP has a typical
PTS1-signal involving AKL as the terminal three amino
acids. This signal has been shown to be both necessary
and sufficient to target peroxisomal-matrix proteins to
peroxisomes (Subramani 1996; Erdmann et al. 1997).
The mislocalized truncated protein is probably unstable
in the cytosol as reflected in the absence of any cross-
reactive immunological material of the expected size as
shown by immunoblot analysis. However, although it is
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Table 2
Analysis of the D-BP Encoding cDNA in Nine Patients Previously
Classified as L-BP Deficient
cDNA Sourcea Mutation Coding Effect
Patient 1 1438-1503del del480-501
Patient 2 1438-1503del del480-501
Patient 3 46GrAb Gly16Ser
Patient 4 46GrAb Gly16Ser
Patient 5 46GrAb Gly16Ser
Patient 6 281-622del del94-208
Patient 7 46GrAb Gly16Ser
Patient 8 63GrT Leu21Phe
Patient 9 869-881del Frameshift
a The patients were identified by complementation analysis as de-
scribed elsewhere by van Grunsven and Wanders (1997).
b This mutation was found in a patient described elsewhere by van
Grunsven et al. (1998).
an unlikely hypothesis, it cannot be excluded that the
truncated protein lacks the epitope for recognition by
the antibody used. In fibroblasts from Zellweger pa-
tients, the full-length protein is present in about half the
normal amounts, but the processed components are
completely absent. We hypothesize that the full-length
D-BP is processed after transport into the peroxisome.
Therefore, the full-length D-BP is present in the cytosol,
which explains why the cytosolic labeling in Zellweger
patients is more pronounced than that in cells from the
index patient T.C. (fig. 1b and c). Since D-BP cannot be
transported into peroxisomes in Zellweger patients, D-
BP will not be processed, which explains why only the
full-length protein is detected.
The data we obtained with L-BP suggest that L-BP is
normally expressed in the patient’s fibroblasts and liver
tissue and show that L-BP deficiency is definitely not the
cause of the defect in peroxisomal b-oxidation in this
patient. We conclude this from the normal presence of
L-BP as shown by immunoblot analysis (fig. 1b) and the
identification of one mRNA species without mutations.
The second mRNA was found to contain two mutations
causing amino acid substitutions at positions 684
(ArgrGly) and 689 (IlerThr). The consequences of
these mutations for the L-BP protein generated have not
been studied, since the product of the other allele will
be completely normal. This means that the patient is
either homozygously normal or heterozygously normal
for L-BP.
The data presented in this paper that show the normal
presence of L-BP when immunoblot analysis is per-
formed are difficult to reconcile with the earlier data
from Watkins et al. (1989). The most likely explanation
for these discrepant results would be that the previously
used antibody (Furuta et al. 1980) was directed primarily
against the D-BP. It should be mentioned that the two
bifunctional proteins have almost identical molecular
weights and show comparable behavior as shown by
chromatography. Unfortunately, this possibility cannot
be investigated, since the antibody used in these earlier
studies is no longer available.
Taken together, the data presented here show that the
actual defect in the patient described by Watkins et al.
(1989) is not at the level of L-BP but at the level of D-
BP. This finding is of importance, especially since cells
from this patient with presumed L-BP deficiency have
been used in several complementation studies as a ref-
erence cell line to classify patients with an unknown
defect in peroxisomal b-oxidation (Wanders et al. 1992;
McGuinness et al. 1993; Suzuki et al. 1994; Moser et
al. 1995; Watkins et al. 1995; Paton et al. 1996; Wanders
et al. 1996; van Grunsven et al. 1997; van Grunsven
and Wanders 1997). In one of our earlier studies (van
Grunsven and Wanders 1997) we identified nine patients
with presumed L-BP deficiency on the basis of comple-
mentation analysis. Mutation analysis of L-BP cDNA in
these patients revealed no abnormalities. However, in all
patients studied, clear mutations in the D-BP cDNAs
were found (table 2). We found four patients with ho-
mozygous deletions: a 66-bp deletion leading to an in-
frame deletion of 22 amino acids (two patients); a 342-
bp deletion leading to an in-frame deletion of 114 amino
acids; and a 13-bp deletion that caused a frameshift re-
sulting in a truncated protein. Four patients were ho-
mozygous for a Gly16Ser mutation, which is in the de-
hydrogenase-coding part of the gene. The glycine at
position 16 is in the Rossman fold forming the
NAD–binding site (see van Grunsven et al. 1998). One
patient is homozygous for the Leu21Phe mutation. The
leucine at position 21 is also in the Rossman fold form-
ing the NAD–binding site (McKie and Douglas 1991;
Leenders et al. 1994b; Ghosh et al. 1995; Lin et al.
1996).
Recently, we identified a patient with D-BP deficiency
who has the same Gly16Ser mutation as now found in
four additional patients (table 2) (van Grunsven et al.
1998). We have performed complementation analysis
and have found that cells from this particular patient
and the index patient T.C., studied in the present article,
do not show complementation, which is in line with the
view that the molecular defect in both patients is in the
gene coding for D-BP. Our data also provide an expla-
nation for earlier results of Suzuki et al. (1997), who
recently studied two patients whose condition was pre-
viously diagnosed as L-BP deficiency on the basis of com-
plementation analysis. Both patients were indeed found
to be D-BP deficient (Suzuki et al. 1997).
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